ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pediatrics"

  • Abstract Number: 050 • 2023 Pediatric Rheumatology Symposium

    Predictive Value of the 2019 EULAR/ACR SLE Criteria’s Extra-Renal Domains to Renal Response One Year After Treatment in a Pediatric Lupus Nephritis Cohort

    Sara Patrizi1, Megha Tandel2, Derek Boothroyd2 and Joyce Hsu1, 1Stanford Medicine, Children's Health, Palo Alto, CA, 2Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: In 2019, new classification criteria for SLE were developed by the EULAR/ACR. Prior research in adult lupus cohorts found a positive correlation between high…
  • Abstract Number: 042 • 2020 Pediatric Rheumatology Symposium

    Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions

    Mary Culp 1, Dusty Lewis 1, Bethanne Thomas 2, Fatima Barbar-Smiley 3, Kyla Driest 4, Edward Oberle 4, Stacy Ardoin 1 and Kelly Wise1, 1Nationwide Children's Hospital, Columbus, 2Nationwide Children's, Columbus, 3Nationwide Children's Hospital, Columbus, Ohio, 4Division of Rheumatology, Nationwide Children's Hospital, Columbus

    Background/Purpose: Infliximab is an effective treatment for many pediatric rheumatic conditions, but high medication cost creates a barrier to patient access. Biosimilar drugs are proven…
  • Abstract Number: 061 • 2020 Pediatric Rheumatology Symposium

    Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis

    Farzana Nuruzzaman1, Mingqian Huang 2, Christian Hedrich 3, Hermann Girschick 4, Julie Cherian 1, Karen Onel 5, T. Shawn Sato 6, Polly Ferguson 7 and Yongdong Zhao 8, 1Stony Brook Children's Hospital, Stony Brook, 2Mount Sinai Hospital, New York, New York, 3University of Liverpool, Liverpool, United Kingdom, 4Wuerzburg, Germany, 5Hospital for Special Surgery, New York, 6University of Iowa, Iowa City, 7University of Iowa Carver College of Medicine, Iowa City, 8University of Washington, Seattle

    Background/Purpose: Radiological imaging is integral to the diagnosis of chronic nonbacterial osteomyelitis (CNO) and has been included as a central component in suggested diagnostic criteria…
  • Abstract Number: 066 • 2020 Pediatric Rheumatology Symposium

    Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated?

    Sai Sudha Mannemuddhu1, Lawrence Shoemaker 2, Shahab Bozorgmehri 3, Roberto Borgia 4, Nirupama Gupta 4, Larry Patterson 3, Kiran Upadhyay 3, Rupam Ruchi 3, Melissa Elder 4, Akaluck Thatayatikom 4, William Clapp 3, Xu Zeng 3 and Renee Modica 5, 1University of Florida, Gainesville, FL., Gainesville, 2University of Florida, Gainesville, Florida, 3University of Florida- College of Medicine, Gainesville, 4University of Florida, Gainesville, 5University of Florida, Gainseville, Orlando

    Background/Purpose: Lupus nephritis (LN) is seen in 20–75% of patients with pediatric Systemic Lupus Erythematosus (SLE). LN may present with abnormal urinary findings and/or renal…
  • Abstract Number: 093 • 2020 Pediatric Rheumatology Symposium

    Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

    Ginger Janow 1, Timothy Beukelman 2, Yukiko Kimura 3, Rayfel Schneider 4, Shalini Mohan 5, Gail Rodich 6 and Mary Beth Son7 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, New Jersey, 2University of Alabama at Birmingham, Birmingham, 3Hackensack Meridian School of Medicine, Hackensack, 4The Hospital for Sick Children, Toronto, Canada, 5Genentech, Inc., South San Francisco, 6Genentech, Mill Valley, 7Boston Children's Hospital, Boston, Massachusetts

    Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes.  There may…
  • Abstract Number: 135 • 2020 Pediatric Rheumatology Symposium

    Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression

    Paivi Miettunen1, Chloe Stephenson 1, Seemab Haider 1, Seamus Stephenson 2, Vijay Moorjani 2 and Rondald Anderson 2, 1University of Calgary, Calgary, Alberta, Canada, 2University of Calgary, Calgary, Canada

    Background/Purpose: Osteonecrosis has emerged as debilitating complication of acute pediatric lymphoblastic leukemia (pALL), with severe pain and poor functional outcome. Patients with ON of weight…
  • Abstract Number: 176 • 2020 Pediatric Rheumatology Symposium

    Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus

    Camille Wilson1, Alana Leever 1, Jennifer Cass 1, Vidya Sivaraman 2 and Stacy Ardoin 1, 1Nationwide Children's Hospital, Columbus, 2Division of Rheumatology, Nationwide Children's Hospital, Bexley

    Background/Purpose: Research has established that a large percentage of individuals diagnosed with childhood-onset systemic lupus erythematosus (cSLE) report cognitive dysfunction. Disease factors that can impact…
  • Abstract Number: 192 • 2020 Pediatric Rheumatology Symposium

    Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease

    Stephen Wong1, Amy Gaultney 2 and Deborah McCurdy 3, 1University of California Los Angeles, Los Angeles, California, 2UCLA, Los Angeles, California, 3UCLA Medical Center, Los Angeles, California

    Background/Purpose: Many children with rheumatic diseases require immunosuppressive treatments, however these medications put them at risk for contracting opportunistic infections leading to severe morbidity and…
  • Abstract Number: 1729 • 2019 ACR/ARP Annual Meeting

    Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India

    Sumidha Mittal 1, Manjari Agarwal 1 and Sujata Sawhney1, 1Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India

    Background/Purpose: Children with systemic lupus erythematosus(cSLE) have more severe disease as compared to adults. Additionally, Asians in their geographic area have high burden of infections…
  • Abstract Number: 1754 • 2019 ACR/ARP Annual Meeting

    Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain

    Matthew Taylor 1, Sabrina Gmuca 2, Lakshmi Moorthy 3, Alexis Boneparth 4 and Daniel Horton3, 1Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 4Columbia University Medical Center, New York, NY

    Background/Purpose: Chronic musculoskeletal (MSK) pain has been associated with chronic illnesses, including mental disorders, and with high rates of pain medication use, often in referral…
  • Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting

    Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?

    Ryan Funk1, Valentina Shakhnovich2, Leon van Haandel3 and Mara L Becker4, 1University of Kansas Medical Center, Kansas City, KS, 2Gastroenterology and Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, 3Clinical Pharmacology, Medical Toxicology, and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, 4Rheumatology, Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…
  • Abstract Number: 2997 • 2017 ACR/ARHP Annual Meeting

    Patient and Family Reported Psychosocial Areas of Concern within Pediatric Rheumatology: Quality Improvement Data and Implications for Practice

    Nicole Tennermann and Melissa Hazen, Rheumatology, Boston Children's Hospital, Boston, MA

    Background/Purpose: Psychosocial factors greatly impact the subjective disease experience and outcomes of children with rheumatic conditions. Attention to the psychosocial aspects of patients’ needs is…
  • Abstract Number: 42 • 2017 Pediatric Rheumatology Symposium

    Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis

    Navita L. Mallalieu1, Joy Hsu1, Karen Wang1, Sunethra Wimalasundera2, Chris Wells2, Inmaculada Calvo Penades3, Rubén J. Cuttica4, Hans-Iko Huppertz5, Rik Joos6, Yukiko Kimura7, Diana Milojevic8, Margalit Rosenkranz9, Kenneth Schikler10, Tamas Constantin11 and Carine Wouters12, 1Roche Innovation Center, New York, NY, 2Roche Products Ltd., Welwyn Garden City, United Kingdom, 3Hospital Universitario y Polytécnico La Fe, Valencia, Spain, 4Hospital General de Niños Pedro de Elizalde, Buenes Aires, Argentina, 5Professor Hess Children's Hospital, Bremen, Germany, 6ZNA Jan Palfijn Antwerpen, Antwerp, Belgium, 7Hackensack University Medical Center, Hackensack, NJ, 8Tufts Medical Center, Boston, MA, 9Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 10University of Louisville Hospital, Louisville, KY, 11Semmelweis University, Budapest, Hungary, 12University Hospital Gasthuisberg, Leuven, Belgium

    Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…
  • Abstract Number: 100 • 2017 Pediatric Rheumatology Symposium

    Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment

    Akaluck Thatayatikom1, Renee F Modica2, Daniel S. Hammenfors3, Natalie Jane Shiff1 and Melissa E Elder2, 1Pediatrics, University of Florida, Gainesville, FL, 2Department of Pediatrics, University of Florida, Gainesville, FL, 3Department of Rheumatology, Haukeland University Hospital, Bergen, Norway

    Background/Purpose:  Juvenile Sjögren’sSyndrome (jSS) is a rare systemic autoimmune disease affecting predominantly salivary glands (SG) in children who do not meet criteria for SLE or MCTD. Currently, no specific criteria for…
  • Abstract Number: 1391 • 2016 ACR/ARHP Annual Meeting

    Novel Electronic Health Record-Based Method Confirms Increased Renal Disease Burden in Pediatric-Onset Vs. Adult-Onset Patients with Systemic Lupus Erythematosus

    April Barnado1, Robert Carroll2, Carolyn Casey1, Joshua C. Denny2 and Leslie J. Crofford3, 1Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 3Medicine, Vanderbilt University Medical Center, Nasville, TN

    Background/Purpose: Children with Systemic Lupus Erythematosus (SLE) are often understudied compared with adults. Using the electronic health record (EHR) can increase sample size and the…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology